How big is Kiniksa Pharmaceuticals Ltd.?

As of Jun 18, Kiniksa Pharmaceuticals Ltd. has a market capitalization of 1,174.17 million and reported net sales of 481.16 million with a net loss of 16.95 million over the latest four quarters.

As of Jun 18, Kiniksa Pharmaceuticals Ltd. has a market capitalization of 1,174.17 million, classifying it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 481.16 million for the latest four quarters, while the net profit for the same period was a loss of 16.95 million.<BR><BR>As of Dec 24, the company's shareholder's funds amounted to 438.44 million, and total assets were reported at 580.55 million.

What does Kiniksa Pharmaceuticals Ltd. do?

Kiniksa Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on developing therapeutic medicines for debilitating diseases. As of March 2025, it reported net sales of $138 million and a market cap of approximately $1.17 billion.

Overview:<BR>Kiniksa Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 138 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 9 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 1,174.17 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.58 <BR>Return on Equity: -3.71% <BR>Price to Book: 2.57<BR><BR>Contact Details:<BR>Address: Clarendon House, 2 Church Street, HAMILTON MA : HM11 <BR>Tel: 1 441 7814399100 <BR>Website: http://www.kiniksa.com/

Should I buy, sell or hold Kiniksa Pharmaceuticals Ltd.?

Who are in the management team of Kiniksa Pharmaceuticals Ltd.?

As of March 2022, the management team of Kiniksa Pharmaceuticals Ltd. includes Mr. Sanjiv Patel (Chairman and CEO), Dr. Felix Baker (Lead Independent Director), and Directors Mr. G. Bradley Cole, Dr. Stephen Biggar, Dr. Richard Levy, and Mr. Thomas Malley.

As of March 2022, the management team of Kiniksa Pharmaceuticals Ltd. includes the following individuals:<BR><BR>- Mr. Sanjiv Patel, who serves as the Chairman of the Board and Chief Executive Officer.<BR>- Dr. Felix Baker, who is the Lead Independent Director.<BR>- Mr. G. Bradley Cole, who is a Director.<BR>- Dr. Stephen Biggar, who is an Independent Director.<BR>- Dr. Richard Levy, who is also an Independent Director.<BR>- Mr. Thomas Malley, who serves as an Independent Director.

Is Kiniksa Pharmaceuticals Ltd. overvalued or undervalued?

As of July 29, 2025, Kiniksa Pharmaceuticals Ltd. is considered an attractive investment due to its undervaluation despite a high P/E ratio of 294.42, strong year-to-date returns of 81.60%, and favorable comparisons to peers like Amneal Pharmaceuticals and NewAmsterdam Pharma.

As of 29 July 2025, the valuation grade for Kiniksa Pharmaceuticals Ltd. moved from risky to attractive, indicating a more favorable outlook. The company appears to be undervalued, particularly when considering its Price to Book Value of 2.78, EV to Sales ratio of 2.09, and a notably high P/E ratio of 294.42, which reflects its loss-making status but suggests potential for future growth. <BR><BR>In comparison with peers, Kiniksa's valuation metrics stand out, especially against Amneal Pharmaceuticals, which has a P/E of 48.88, and NewAmsterdam Pharma, which shows a negative P/E. Despite recent stock performance showing a decline of 2.95% over the past week compared to a 1.05% increase in the S&P 500, Kiniksa has demonstrated strong returns year-to-date at 81.60%, significantly outperforming the S&P 500's 12.22%. This combination of metrics and performance suggests that Kiniksa Pharmaceuticals Ltd. may be a compelling investment opportunity.

Is Kiniksa Pharmaceuticals Ltd. technically bullish or bearish?

As of August 26, 2025, Kiniksa Pharmaceuticals Ltd. shows a strong bullish trend supported by positive technical indicators, outperforming the S&P 500 with an 81.60% year-to-date return compared to 12.22%.

As of 26 August 2025, the technical trend for Kiniksa Pharmaceuticals Ltd. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both the weekly and monthly time frames, and the moving averages are bullish on the daily time frame. Additionally, the KST and Dow Theory both indicate a bullish trend on weekly and monthly bases. Bollinger Bands show a mildly bullish signal weekly and bullish monthly. <BR><BR>In terms of performance, Kiniksa has significantly outperformed the S&P 500 year-to-date with a return of 81.60% compared to the S&P 500's 12.22%. Over the past year, Kiniksa has returned 42.14% against the S&P 500's 17.14%. Overall, the technical indicators suggest a strong bullish sentiment for Kiniksa Pharmaceuticals Ltd.